@boulware_dr @DrLuisO One of the most egregious acts was the federal court making a common statistical mistake on Vascepa and then watching the appeals court and the SCOTUS defend the ruling https://t.co/Yja85mndsv https://t.co/2jTFhP2bfL The generics w
$amrn does today’s cafc patent ruling stop future innovations in CV space because the patents were invalidated based on a flawed scientific analysis. Not sure how future drugs in CV can get around this ruling.
Just a reminder, Nature : $AMRN justice may reverse a judgement based on a common statistical mistake. If the decision is allowed to stand, it will have major implications for pharmaceutical patents and biomedical innovation. $ibb $spy $qqq https://t.
RT @Everyonelovesi1: @OurNevadaJudges You all should be proud of the Honorable Judge Du - she gets an honorable mention here....well done…
a call to rigor in statistics ... just like in basic research: you don't always know what the results will lead to. Sometimes, bad statistics can lead to economic damage. https://t.co/nNrHFSzEHo https://t.co/XomvbrYVGc
RT @Everyonelovesi1: @OurNevadaJudges You all should be proud of the Honorable Judge Du - she gets an honorable mention here....well done…
RT @DLBHATTMD: Just out in @NatureBiotech with Dr. Gregory Curfman from @JAMA_current and Dr. Michael Pencina from @DCRINews - our article…
At a time when more innovation is required than ever due to . #COVID19 Natrure : tell us why $AMRN should win the appeal. . https://t.co/4cz7y8FfbC $xbi $ibb $qqq $spy
RT @joaquinkam: Nature : $AMRN justice should reverse judgement based on a common statistical mistake. If the decision is allowed to stan…
Nature : $AMRN justice should reverse judgement based on a common statistical mistake. If the decision is allowed to stand, it will have major implications for pharmaceutical patents and biomedical innovation. $ibb $spy $qqq https://t.co/4cz7y8FfbC
Quiere un texto con un caso reciente y aplicado para usar en un curso de protección intelectual de fármacos?...pues disfrútelo y comparta https://t.co/SF1taMOhJt
RT @DLBHATTMD: Just out in @NatureBiotech with Dr. Gregory Curfman from @JAMA_current and Dr. Michael Pencina from @DCRINews - our article…
RT @NatureBiotech: Federal judge invalidates icosapent ethyl patents — but on the basis of a common statistical mistake. If allowed to stan…
RT @NatureBiotech: Federal judge invalidates icosapent ethyl patents — but on the basis of a common statistical mistake. If allowed to stan…
RT @NatureBiotech: Federal judge invalidates icosapent ethyl patents — but on the basis of a common statistical mistake. If allowed to stan…
Federal judge invalidates icosapent ethyl patents — but on the basis of a common statistical mistake. If allowed to stand, the decision will have major implications for pharmaceutical patents and biomedical innovation https://t.co/QnAj9uvp9A
RT @DLBHATTMD: Just out in @NatureBiotech with Dr. Gregory Curfman from @JAMA_current and Dr. Michael Pencina from @DCRINews - our article…
RT @yudi_lks: @Amarincorp $AMRN WISH Judges would read this: https://t.co/GZ2IMrbXnf
RT @DLBHATTMD: Just out in @NatureBiotech with Dr. Gregory Curfman from @JAMA_current and Dr. Michael Pencina from @DCRINews - our article…
@Amarincorp WISH Judges would read this: https://t.co/GZ2IMrbXnf
@Amarincorp $AMRN WISH Judges would read this: https://t.co/GZ2IMrbXnf
RT @DLBHATTMD: Just out in @NatureBiotech with Dr. Gregory Curfman from @JAMA_current and Dr. Michael Pencina from @DCRINews - our article…
RT @DLBHATTMD: Just out in @NatureBiotech with Dr. Gregory Curfman from @JAMA_current and Dr. Michael Pencina from @DCRINews - our article…
RT @DLBHATTMD: Just out in @NatureBiotech with Dr. Gregory Curfman from @JAMA_current and Dr. Michael Pencina from @DCRINews - our article…
While Pharmaceutical companies risk millions of dollars on research and development of useful interventions that improve patients outcomes, Governments are not necessarily willing to take that risk. They are undenibly critical players for improving medical
RT @DLBHATTMD: Just out in @NatureBiotech with Dr. Gregory Curfman from @JAMA_current and Dr. Michael Pencina from @DCRINews - our article…
@USAO_NV @SKDC_Nevada @CourtsNevada
RT @Everyonelovesi1: @OurNevadaJudges You all should be proud of the Honorable Judge Du - she gets an honorable mention here....well done…
@OurNevadaJudges You all should be proud of the Honorable Judge Du - she gets an honorable mention here....well done https://t.co/lFRlkmJgx4 $AMRN
RT @DLBHATTMD: Just out in @NatureBiotech with Dr. Gregory Curfman from @JAMA_current and Dr. Michael Pencina from @DCRINews - our article…
@rickberke @adamfeuerstein @statnews Just an FYI that might interest Adam https://t.co/HRW1Cvq3vj
RT @DLBHATTMD: Just out in @NatureBiotech with Dr. Gregory Curfman from @JAMA_current and Dr. Michael Pencina from @DCRINews - our article…
RT @DLBHATTMD: Just out in @NatureBiotech with Dr. Gregory Curfman from @JAMA_current and Dr. Michael Pencina from @DCRINews - our article…
$AMRN
$Amrn
RT @DLBHATTMD: Just out in @NatureBiotech with Dr. Gregory Curfman from @JAMA_current and Dr. Michael Pencina from @DCRINews - our article…
RT @DLBHATTMD: Just out in @NatureBiotech with Dr. Gregory Curfman from @JAMA_current and Dr. Michael Pencina from @DCRINews - our article…
Just out in @NatureBiotech with Dr. Gregory Curfman from @JAMA_current and Dr. Michael Pencina from @DCRINews - our article on the implications of patent decisions made on the basis of flawed statistics on future innovation: https://t.co/axm9zUANjQ #Cardio